As a proof-of-concept, we decided to target ER/PI3K interactions using an anti-estrogen (fulvestrant) or a PI3K inhibitor alone (BYL719) or in combination in 6 models of ER+ and 3 ER BC PDXs. The gene discussed is ESR1; the disease is breast cancer.